We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RGEN:NASDAQRepligen Corporation Analysis

Data as of 2026-07-08 - not real-time

$137.41

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Repligen posted solid double‑digit revenue growth and improved margins, supported by a strong cash position that exceeds its debt load. However, earnings per share remain modest and the company carries a high debt‑to‑equity ratio, which tempers the upside from its growth narrative.
Technical indicators show a neutral price trend but a bearish MACD crossover and a widening histogram, while market sentiment is extremely bullish, pushing the stock well above its discounted cash‑flow estimate. The combination of an elevated price multiple, high volatility and a substantial drawdown history signals that the current price may be stretched, suggesting caution for short‑term traders despite the underlying business momentum.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • bearish MACD histogram
  • price near recent support level
  • significant overvaluation relative to peers

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • steady revenue growth and margin expansion
  • high cash generation offset by debt load
  • persistent market enthusiasm keeping price elevated

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • strong fundamentals in a growing bioprocessing market
  • absence of dividend limits total return expectations
  • valuation gap suggests price correction before long‑term upside

Key Metrics & Analysis

Financial Health

Revenue Growth14.80%
Profit Margin6.73%
P/E Ratio151.0
ROE2.51%
ROA1.18%
Debt/Equity32.66
P/B Ratio3.7
Op. Cash Flow$130.7M
Free Cash Flow$68.7M
Industry P/E29.2

Technical Analysis

TrendNeutral
RSI55.5
Support$124.85
Resistance$149.05
MA 20$135.50
MA 50$124.49
MA 200$139.32
MACDBearish
VolumeIncreasing
Fear & Greed Index91.25

Valuation

Fair Value$31.13
Target Price$177.05
Upside/Downside28.85%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.24
Volatility51.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.